Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARTACUS Trial: Sotagliflozin for Prevention of Anthracycline-Related Cardiotoxicity
NCT07572175Phase 2Not yet recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jul 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sotagliflozin in Cardiotoxicity, sponsored by Icahn School of Medicine at Mount Sinai. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sotagliflozin
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT07572175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572175.